Abstract

BackgroundCardiovascular disease (CVD) is a major cause of morbidity and mortality among people living with HIV (PLWH), but statin therapy, safe and effective for PLWH, is under-prescribed. This study examined clinic leadership and provider perceptions of factors associated with statin prescribing for PLWH receiving care in eight community health clinics across Los Angeles, California.MethodsWe conducted semi-structured telephone interviews with clinic leadership and providers across community health clinics participating in a larger study (INSPIRE) aimed at improving statin prescribing through education and feedback. Clinics included federally qualified health centers (N = 5), community clinics (N = 1) and county-run ambulatory care clinics (N = 2). Leadership and providers enrolled in INSPIRE (N = 39) were invited to participate in an interview. We used the Consolidated Framework for Implementation Research (CFIR) to structure our interview guide and analysis. We used standard qualitative content analysis methods to identify themes within CFIR categories; we also assessed current CVD risk assessment and statin-prescribing practices.ResultsParticipants were clinic leaders (n = 6), primary care physicians with and without an HIV specialization (N = 6, N = 6, respectively), infectious diseases specialists (N = 12), nurse practitioners, physician assistants and registered nurses (N = 7). Ninety-five percent of providers from INSPIRE participated in an interview. We found that CVD risk assessment for PLWH is standard practice but that there is variation in risk assessment practices and that providers are unsure whether or how to adjust the risk threshold to account for HIV. Time, clinic and patient priorities impede ability to conduct CVD risk assessment with PLWH.ConclusionsProviders desire more data and standard practice guidance on prescribing statins for PLWH, including estimates of the effect of HIV on CVD, how to adjust the CVD risk threshold to account for HIV, which statins are best for people on antiretroviral therapy and on shared decision-making around prescribing statins to PLWH. While CVD risk assessment and statin prescribing fits within the mission and workflow of primary care, clinics may need to emphasize CVD risk assessment and statins as priorities in order to improve uptake.

Highlights

  • Cardiovascular disease (CVD) is a major cause of morbidity and mortality among people living with HIV (PLWH), but statin therapy, safe and effective for PLWH, is under-prescribed

  • Study setting Data was collected from clinic leadership and providers participating in the INSPIRE study. (This article refers to all physicians, nurse practitioners (NP), physician assistants (PA), and registered nurses (RN) who participated in the study as “providers,” but differentiates between provider types where relevant differences emerged.) The study is taking place in eight public community health clinics in Los Angeles County, California that serve PLWH

  • Themes We first describe themes within the domain Current Practices; we present themes that emerged within the modified Consolidated Framework for Implementation Research (CFIR) domains: Characteristics of Statins, Characteristics of Providers, Inner Setting, and Patient Factors

Read more

Summary

Introduction

Cardiovascular disease (CVD) is a major cause of morbidity and mortality among people living with HIV (PLWH), but statin therapy, safe and effective for PLWH, is under-prescribed. As life expectancy of people living with HIV (PLWH) approaches that of HIV-uninfected adults, [1, 2] prevention of cardiovascular disease (CVD) has become critical for decreasing morbidity and mortality among PLWH. The QRISK3 found that HIV was associated with a 25% increased risk in women and a 17% increased risk in men While these risk estimates did not meet statistical significance at the 0.01 level potentially due to a relatively low event rate in PLWH attributable to the cohort’s younger age, [13] multiple modeling and epidemiologic studies overall have found that increased cardiovascular risk among patients with HIV [3,4,5,6]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call